Cannabidiol oral formulation - Receptor Life Sciences
Alternative Names: RLS-102Latest Information Update: 28 Aug 2024
At a glance
- Originator Receptor Life Sciences
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Agitation
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Agitation(In volunteers) in USA (PO, Capsule)
- 03 Aug 2021 Cannabidiol - Receptor Life Sciences is available for licensing in Canada, Europe as of 03 Aug 2021. https://www.receptorlife.com/
- 19 Jul 2021 Phase-I clinical trials in Agitation (In volunteers) in USA (PO)